Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Branded Generics Escape Indian Trade Margin Limits

This article was originally published in PharmAsia News

Executive Summary

Generic drugs with brand names in India could be excluded from the government's proposal to restrict trade margins. The exclusion would cover drug makers such as Cadita Healthcare, GlaxoSmithKline, Nicholas Piramal and Ranbaxy, all of which sell generics under brand names rather than chemical names. Those brand names place the drugs in another category under Indian law. Makers of the branded generics allow retail pharmacies a trade margin as high as 29 times the manufactured price. (Click here for more

You may also be interested in...



ECHA's ‘Devastating Blow’ To Animal Testing Ban Slammed By Cosmetic Industry, Stakeholders

In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.

Pink Sheet Podcast: UK Clears COVID-19 Vaccine, FDA Pressure Increases; Biden’s FDA Commissioner

Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.

LivaNova Sells Surgical Heart Valve Business To Gyrus Capital For $73M

Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel